Cargando…

A new KIF5B–ERBB4 gene fusion in a lung adenocarcinoma patient

ERBB4 fusion is a rare, novel oncogenic event involved in the development of lung adenocarcinoma that is not routinely looked for, although ERBB4 fusion is a potential target for existing pan-ErbB tyrosine kinase and must be implemented in the laboratory https://bit.ly/3nYmGQ9

Detalles Bibliográficos
Autores principales: Guenzi, Edouard, Pluvy, Johan, Guyard, Alice, Nguenang, Marina, Rebah, Khedidja, Benrahmoune, Zoubida, Lamoril, Jérome, Cazes, Aurelie, Gounant, Valérie, Brosseau, Solenn, Boileau, Catherine, Zalcman, Gérard, Théou-Anton, Nathalie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8005686/
https://www.ncbi.nlm.nih.gov/pubmed/33816604
http://dx.doi.org/10.1183/23120541.00582-2020
_version_ 1783672162583838720
author Guenzi, Edouard
Pluvy, Johan
Guyard, Alice
Nguenang, Marina
Rebah, Khedidja
Benrahmoune, Zoubida
Lamoril, Jérome
Cazes, Aurelie
Gounant, Valérie
Brosseau, Solenn
Boileau, Catherine
Zalcman, Gérard
Théou-Anton, Nathalie
author_facet Guenzi, Edouard
Pluvy, Johan
Guyard, Alice
Nguenang, Marina
Rebah, Khedidja
Benrahmoune, Zoubida
Lamoril, Jérome
Cazes, Aurelie
Gounant, Valérie
Brosseau, Solenn
Boileau, Catherine
Zalcman, Gérard
Théou-Anton, Nathalie
author_sort Guenzi, Edouard
collection PubMed
description ERBB4 fusion is a rare, novel oncogenic event involved in the development of lung adenocarcinoma that is not routinely looked for, although ERBB4 fusion is a potential target for existing pan-ErbB tyrosine kinase and must be implemented in the laboratory https://bit.ly/3nYmGQ9
format Online
Article
Text
id pubmed-8005686
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher European Respiratory Society
record_format MEDLINE/PubMed
spelling pubmed-80056862021-04-02 A new KIF5B–ERBB4 gene fusion in a lung adenocarcinoma patient Guenzi, Edouard Pluvy, Johan Guyard, Alice Nguenang, Marina Rebah, Khedidja Benrahmoune, Zoubida Lamoril, Jérome Cazes, Aurelie Gounant, Valérie Brosseau, Solenn Boileau, Catherine Zalcman, Gérard Théou-Anton, Nathalie ERJ Open Res Original Research Letters ERBB4 fusion is a rare, novel oncogenic event involved in the development of lung adenocarcinoma that is not routinely looked for, although ERBB4 fusion is a potential target for existing pan-ErbB tyrosine kinase and must be implemented in the laboratory https://bit.ly/3nYmGQ9 European Respiratory Society 2021-03-29 /pmc/articles/PMC8005686/ /pubmed/33816604 http://dx.doi.org/10.1183/23120541.00582-2020 Text en Copyright ©The authors 2021 http://creativecommons.org/licenses/by-nc/4.0/This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org (mailto:permissions@ersnet.org)
spellingShingle Original Research Letters
Guenzi, Edouard
Pluvy, Johan
Guyard, Alice
Nguenang, Marina
Rebah, Khedidja
Benrahmoune, Zoubida
Lamoril, Jérome
Cazes, Aurelie
Gounant, Valérie
Brosseau, Solenn
Boileau, Catherine
Zalcman, Gérard
Théou-Anton, Nathalie
A new KIF5B–ERBB4 gene fusion in a lung adenocarcinoma patient
title A new KIF5B–ERBB4 gene fusion in a lung adenocarcinoma patient
title_full A new KIF5B–ERBB4 gene fusion in a lung adenocarcinoma patient
title_fullStr A new KIF5B–ERBB4 gene fusion in a lung adenocarcinoma patient
title_full_unstemmed A new KIF5B–ERBB4 gene fusion in a lung adenocarcinoma patient
title_short A new KIF5B–ERBB4 gene fusion in a lung adenocarcinoma patient
title_sort new kif5b–erbb4 gene fusion in a lung adenocarcinoma patient
topic Original Research Letters
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8005686/
https://www.ncbi.nlm.nih.gov/pubmed/33816604
http://dx.doi.org/10.1183/23120541.00582-2020
work_keys_str_mv AT guenziedouard anewkif5berbb4genefusioninalungadenocarcinomapatient
AT pluvyjohan anewkif5berbb4genefusioninalungadenocarcinomapatient
AT guyardalice anewkif5berbb4genefusioninalungadenocarcinomapatient
AT nguenangmarina anewkif5berbb4genefusioninalungadenocarcinomapatient
AT rebahkhedidja anewkif5berbb4genefusioninalungadenocarcinomapatient
AT benrahmounezoubida anewkif5berbb4genefusioninalungadenocarcinomapatient
AT lamoriljerome anewkif5berbb4genefusioninalungadenocarcinomapatient
AT cazesaurelie anewkif5berbb4genefusioninalungadenocarcinomapatient
AT gounantvalerie anewkif5berbb4genefusioninalungadenocarcinomapatient
AT brosseausolenn anewkif5berbb4genefusioninalungadenocarcinomapatient
AT boileaucatherine anewkif5berbb4genefusioninalungadenocarcinomapatient
AT zalcmangerard anewkif5berbb4genefusioninalungadenocarcinomapatient
AT theouantonnathalie anewkif5berbb4genefusioninalungadenocarcinomapatient
AT guenziedouard newkif5berbb4genefusioninalungadenocarcinomapatient
AT pluvyjohan newkif5berbb4genefusioninalungadenocarcinomapatient
AT guyardalice newkif5berbb4genefusioninalungadenocarcinomapatient
AT nguenangmarina newkif5berbb4genefusioninalungadenocarcinomapatient
AT rebahkhedidja newkif5berbb4genefusioninalungadenocarcinomapatient
AT benrahmounezoubida newkif5berbb4genefusioninalungadenocarcinomapatient
AT lamoriljerome newkif5berbb4genefusioninalungadenocarcinomapatient
AT cazesaurelie newkif5berbb4genefusioninalungadenocarcinomapatient
AT gounantvalerie newkif5berbb4genefusioninalungadenocarcinomapatient
AT brosseausolenn newkif5berbb4genefusioninalungadenocarcinomapatient
AT boileaucatherine newkif5berbb4genefusioninalungadenocarcinomapatient
AT zalcmangerard newkif5berbb4genefusioninalungadenocarcinomapatient
AT theouantonnathalie newkif5berbb4genefusioninalungadenocarcinomapatient